Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
boston blog main
life sciences
national blog main
san francisco blog main
4
×
san francisco top stories
boston top stories
deals
national top stories
new york blog main
new york top stories
startups
biogen
biotech
boston
boulder/denver blog main
boulder/denver top stories
cancer
crispr
deerfield management
detroit blog main
detroit top stories
europe blog main
europe top stories
fda
gilead sciences
indiana blog main
indiana top stories
ipo
melinta therapeutics
national
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
sanofi
seattle blog main
seattle top stories
texas blog main
texas top stories
What
bio
4
×
medicines
4
×
covid
deal
ipo
new
roundup
years
acquisitions
activity
announced
approvals
bets
biogen
cancer
ceo
clamped
collabs
comes
companies
create
crispr
cut
daniel
date
delays
developing
diagnostic
diseases
economic
editing
effective
enticed
evidence
fast
fda
fix
gene
gilead
gilead’s
Language
unset
Current search:
bio
×
photo
×
" san francisco blog main "
×
medicines
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines